1. Home
  2. COHR vs UTHR Comparison

COHR vs UTHR Comparison

Compare COHR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHR
  • UTHR
  • Stock Information
  • Founded
  • COHR 1971
  • UTHR 1996
  • Country
  • COHR United States
  • UTHR United States
  • Employees
  • COHR N/A
  • UTHR N/A
  • Industry
  • COHR Electronic Components
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHR Technology
  • UTHR Health Care
  • Exchange
  • COHR Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • COHR 20.2B
  • UTHR 20.7B
  • IPO Year
  • COHR 1987
  • UTHR 1999
  • Fundamental
  • Price
  • COHR $138.71
  • UTHR $470.12
  • Analyst Decision
  • COHR Strong Buy
  • UTHR Buy
  • Analyst Count
  • COHR 14
  • UTHR 12
  • Target Price
  • COHR $137.77
  • UTHR $495.08
  • AVG Volume (30 Days)
  • COHR 4.9M
  • UTHR 559.2K
  • Earning Date
  • COHR 11-05-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • COHR N/A
  • UTHR N/A
  • EPS Growth
  • COHR N/A
  • UTHR 16.08
  • EPS
  • COHR 0.76
  • UTHR 26.38
  • Revenue
  • COHR $6,043,358,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • COHR $10.48
  • UTHR $13.68
  • Revenue Next Year
  • COHR $11.20
  • UTHR $5.63
  • P/E Ratio
  • COHR $183.08
  • UTHR $17.68
  • Revenue Growth
  • COHR 20.80
  • UTHR 13.50
  • 52 Week Low
  • COHR $45.58
  • UTHR $266.98
  • 52 Week High
  • COHR $168.57
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • COHR 52.40
  • UTHR 67.39
  • Support Level
  • COHR $145.41
  • UTHR $444.04
  • Resistance Level
  • COHR $164.01
  • UTHR $464.27
  • Average True Range (ATR)
  • COHR 9.06
  • UTHR 15.76
  • MACD
  • COHR -0.31
  • UTHR 1.66
  • Stochastic Oscillator
  • COHR 32.39
  • UTHR 84.40

About COHR Coherent Corp.

Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: